TOZARIDE Trademark

Trademark Overview

On Monday, November 20, 2017, a trademark application was filed for TOZARIDE with the United States Patent and Trademark Office. The USPTO has given the TOZARIDE trademark a serial number of 87691768. The federal status of this trademark filing is SECTION 8 - ACCEPTED as of Tuesday, July 8, 2025. This trademark is owned by Andarix Pharmaceuticals, Inc.. The TOZARIDE trademark is filed in the Pharmaceutical Products category with the following description:

Peptide-based pharmaceutical preparations for the treatment of lung cancer
tozaride

General Information

Serial Number87691768
Word MarkTOZARIDE
Filing DateMonday, November 20, 2017
Status701 - SECTION 8 - ACCEPTED
Status DateTuesday, July 8, 2025
Registration Number5650970
Registration DateTuesday, January 8, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 17, 2018

Trademark Statements

Goods and ServicesPeptide-based pharmaceutical preparations for the treatment of lung cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, December 2, 2017
Primary Code005
First Use Anywhere DateMonday, February 1, 2016
First Use In Commerce DateThursday, September 1, 2016

Trademark Owner History

Party NameAndarix Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSomerville, MA 02144
Party NameAndarix Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSomerville, MA 02144
Party NameAndarix Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSomerville, MA 02144

Trademark Events

Event DateEvent Description
Saturday, December 2, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 5, 2018EXAMINERS AMENDMENT -WRITTEN
Monday, March 5, 2018EXAMINER'S AMENDMENT ENTERED
Monday, March 5, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, March 15, 2018ASSIGNED TO LIE
Tuesday, April 17, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, March 5, 2018ASSIGNED TO EXAMINER
Monday, March 5, 2018EXAMINERS AMENDMENT E-MAILED
Monday, March 5, 2018NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, March 28, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 17, 2018PUBLISHED FOR OPPOSITION
Tuesday, June 12, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, November 16, 2018TEAS STATEMENT OF USE RECEIVED
Monday, December 3, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, December 7, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, January 2, 2025TEAS SECTION 8 RECEIVED
Friday, November 16, 2018USE AMENDMENT FILED
Monday, December 3, 2018STATEMENT OF USE PROCESSING COMPLETE
Thursday, December 6, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, January 8, 2019REGISTERED-PRINCIPAL REGISTER
Monday, January 8, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, May 16, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Friday, May 16, 2025POST REGISTRATION ACTION MAILED - SEC. 8
Wednesday, June 11, 2025TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Tuesday, July 8, 2025REGISTERED - SEC. 8 (6-YR) ACCEPTED
Tuesday, July 8, 2025NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED

Related Keywords

tozaride lung cancer treatment preparations based pharmaceutical peptide